Unavailable
Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $BIOA
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/28/2025 | Mkt Perform | William Blair | |
| 12/10/2024 | $40.00 → $5.00 | Overweight → Underweight | Morgan Stanley |
| 12/9/2024 | $42.00 → $7.00 | Buy → Hold | Jefferies |
| 12/9/2024 | $45.00 → $7.00 | Buy → Neutral | Citigroup |
| 10/21/2024 | $45.00 | Buy | Citigroup |
| 10/21/2024 | $42.00 | Buy | Jefferies |
| 10/21/2024 | $40.00 | Overweight | Morgan Stanley |
BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024
Advancement of oral, brain-penetrant NLRP3 inhibitor BGE-102, with initial clinical data expected 2H25 Progression of preclinical next-generation APJ agonists for obesity New platform partnerships with Novartis and Lilly to discover and develop novel therapies for conditions driven by metabolic aging RICHMOND, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging, today provided financial results for the full year ended December 31, 2024 and business updates for the fourth quarter ended Decembe
BioArctic receives Orphan Drug Designation for exidavnemab the US
STOCKHOLM, March 17, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation (ODD) to exidavnemab for the treatment of Multiple System Atrophy (MSA), providing incentives for the development of treatments for rare diseases with a high medical need. Multiple System Atrophy (MSA) is a rapidly progressive and fatal rare disease affecting the central and autonomic nervous systems. MSA is characterized by pathological alpha-synuclein aggregation, that causes gradual damage to nerve cells in the brain. This affects balance, movement and the autonomic nervous system, which
Therapeutic Goods Administration decides not to register lecanemab in Australia
STOCKHOLM, Sweden, March 3, 2025 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ:BIOA) (STOCKHOLM: BIOA B) partner Eisai announced today that the Therapeutic Goods Administration (TGA) of Australia has declined the approval of lecanemab (generic name) as a treatment for early Alzheimer's disease (AD) (mild cognitive impairment due to AD and mild AD dementia). Eisai remains committed to ensuring eligible Australians with early Alzheimer's disease can access lecanemab and is exploring options to achieve this, including potentially seeking review by the Administrative Review Tribunal. In October 2024, the TGA made the decision not to register lecanemab in Australia for the treatment of patients
William Blair initiated coverage on BioAge Labs
William Blair initiated coverage of BioAge Labs with a rating of Mkt Perform
BioAge Labs downgraded by Morgan Stanley with a new price target
Morgan Stanley downgraded BioAge Labs from Overweight to Underweight and set a new price target of $5.00 from $40.00 previously
BioAge Labs downgraded by Jefferies with a new price target
Jefferies downgraded BioAge Labs from Buy to Hold and set a new price target of $7.00 from $42.00 previously
Amendment: Director Hemrajani Rekha bought $54,000 worth of shares (3,000 units at $18.00) (SEC Form 4)
4/A - BioAge Labs, Inc. (0001709941) (Issuer)
Principal Accounting Officer Barton Shane bought $47,376 worth of shares (2,632 units at $18.00) (SEC Form 4)
4 - BioAge Labs, Inc. (0001709941) (Issuer)
Director Pande Vijay Satyanand bought $4,329,019 worth of shares (219,195 units at $19.75) (SEC Form 4)
4 - BioAge Labs, Inc. (0001709941) (Issuer)
Amendment: Director Hemrajani Rekha bought $54,000 worth of shares (3,000 units at $18.00) (SEC Form 4)
4/A - BioAge Labs, Inc. (0001709941) (Issuer)
Principal Accounting Officer Barton Shane bought $47,376 worth of shares (2,632 units at $18.00) (SEC Form 4)
4 - BioAge Labs, Inc. (0001709941) (Issuer)
Amendment: SEC Form 4 filed by Chief Operating Officer Morgen Eric
4/A - BioAge Labs, Inc. (0001709941) (Issuer)
SEC Form S-8 filed by BioAge Labs Inc.
S-8 - BioAge Labs, Inc. (0001709941) (Filer)
SEC Form 10-K filed by BioAge Labs Inc.
10-K - BioAge Labs, Inc. (0001709941) (Filer)
BioAge Labs Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - BioAge Labs, Inc. (0001709941) (Filer)
SEC Form SC 13G filed by BioAge Labs Inc.
SC 13G - BioAge Labs, Inc. (0001709941) (Subject)
SEC Form SC 13G filed by BioAge Labs Inc.
SC 13G - BioAge Labs, Inc. (0001709941) (Subject)
SEC Form SC 13D filed by BioAge Labs Inc.
SC 13D - BioAge Labs, Inc. (0001709941) (Subject)